NKGen Biotech
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3001 Daimler St, Santa Ana, California, ...Phone Number
(949) 396-6830Website
www.nkgenbiotech.comRevenue
-Stock Symbol
NKGNIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
2
2
1
1
1
About NKGen Biotech
NKGen Biotech is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapies to treat neurodegenerative and oncological diseases utilizing our proprietary SNK (super-activated) platform. Spearheading our industry disrupting technology are our Senior Leadership, Senior Advisors and Management Team. Together they bring a wealth of knowledge and expertise in neurodegeneration and immune-oncology and are passionate and excited about the work we are doing to strengthen the immune system.Explore more
NKGen Biotech Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NKGen Biotech your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on NKGen Biotech recently announced quarterly report
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when NKGen Biotech launches new products
Congratulate Masked Content for being promoted to Masked Content at NKGen Biotech
NKGen Biotech, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if NKGen Biotech had a recent Job posting/layoffs
Check out if NKGen Biotech is spiking on competitors!
Check if NKGen Biotech has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once NKGen Biotech has new funding data
Recommended Actions
Reach out to Masked Content who joined NKGen Biotech as Masked Content
Find 2 more new buyers
Compare Similar Companies to NKGen Biotech
Compare insights from companies similar to NKGen Biotech, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
NKGen Biotech is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
NKGen Biotech is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about NKGen Biotech.
NKGen Biotech financials insights
Gather financial insights about NKGen Biotech, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$1M
2024
Debt
$5M
Other Financing Round
$2.8M
2025
Other Financing Round
$2M
NKGen Biotech Tech Stack
A closer look at the technologies used by NKGen Biotech
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
, according to a mid-level source in medical, is in the midst of initiatives related to personalized health.
Healthcare Operations, Patient Experience
Project
, according to a mid-level source in medical, is in the midst of initiatives related to medical equipment.
Healthcare Technology
Project
, according to a mid-level source in medical, is in the midst of initiatives related to remote patient monitoring (RPM). The organization is currently evaluating Optimize Health.
Workforce Management, Patient Experience, Telemedicine
Project
Patient Experience
NKGen Biotech News & Media
NKGen Biotech Expands Clinical Trial Site Network for Alzheimer’s Disease Program Across U.S. to Improve Patient Access and Support Enrollment
New sites in New Jersey, New York, and Florida broaden geographic reach and increase access for patients participating in Phase 2 trial of troculeucel in moderate Alzheimer’s disease.NKGen Biotech secures $39,922,134.22 convertible loan | NKGN 8-K Filing - Stock Titan
NKGen Biotech obtains a $39,922,134.22 secured convertible loan at 12% interest, adds a $0.08 conversion note, warrant, 11,807,380 shares, and broad investor rights over its board, financings and key corporate actions.NKGen Biotech to Present Troculeucel Mechanism Data in Alzheimer’s and Frontotemporal Dementia at the Neuroimmunology Drug Development Summit
SANTA ANA, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that it will present data on its lead investigational program, troculeucel, at the 8th Annual Neuroimmunology Drug Development Summit being held April 14-16, 2026, in Boston, Massachusetts.NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer’s Disease at AD/PD 2026™
Pooled analyses in patients with moderate Alzheimer’s show dose-related cognitive benefit and signs of durability.
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NKGen Biotech
Sign Up For FreeTo access detailed company insights
NKGen Biotech is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapies to treat neurodegenerative and oncological diseases utilizing our proprietary SNK (super-activated) platform. Spearheading our industry disrupting technology are our S... Read More
